WO2006080524A1 - 血糖降下剤を含有する、耐糖能異常、境界型糖尿病、インスリン抵抗性及び高インスリン血症の改善ないし治療用医薬組成物 - Google Patents
血糖降下剤を含有する、耐糖能異常、境界型糖尿病、インスリン抵抗性及び高インスリン血症の改善ないし治療用医薬組成物 Download PDFInfo
- Publication number
- WO2006080524A1 WO2006080524A1 PCT/JP2006/301548 JP2006301548W WO2006080524A1 WO 2006080524 A1 WO2006080524 A1 WO 2006080524A1 JP 2006301548 W JP2006301548 W JP 2006301548W WO 2006080524 A1 WO2006080524 A1 WO 2006080524A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- hyperinsulinemia
- hypoglycemic agent
- insulin resistance
- diabetes
- Prior art date
Links
- 201000009104 prediabetes syndrome Diseases 0.000 title claims abstract description 44
- 206010022489 Insulin Resistance Diseases 0.000 title claims abstract description 35
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims abstract description 31
- 208000002705 Glucose Intolerance Diseases 0.000 title claims abstract description 30
- 206010018429 Glucose tolerance impaired Diseases 0.000 title claims abstract description 26
- 206010060378 Hyperinsulinaemia Diseases 0.000 title claims abstract description 26
- 230000003451 hyperinsulinaemic effect Effects 0.000 title claims abstract description 26
- 201000008980 hyperinsulinism Diseases 0.000 title claims abstract description 26
- 239000003472 antidiabetic agent Substances 0.000 title claims abstract description 25
- 229940126904 hypoglycaemic agent Drugs 0.000 title claims abstract description 23
- 239000000203 mixture Substances 0.000 title abstract description 8
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 34
- 208000001145 Metabolic Syndrome Diseases 0.000 claims abstract description 11
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims abstract description 11
- 230000007211 cardiovascular event Effects 0.000 claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 208000031225 myocardial ischemia Diseases 0.000 claims abstract description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 48
- 102000004877 Insulin Human genes 0.000 claims description 24
- 108090001061 Insulin Proteins 0.000 claims description 24
- 229940125396 insulin Drugs 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 229940122199 Insulin secretagogue Drugs 0.000 claims description 6
- 229940123208 Biguanide Drugs 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 3
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- 229940123452 Rapid-acting insulin Drugs 0.000 claims description 2
- 108010026951 Short-Acting Insulin Proteins 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 230000000580 secretagogue effect Effects 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 34
- 210000004369 blood Anatomy 0.000 description 34
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 31
- 239000008103 glucose Substances 0.000 description 31
- WPGGHFDDFPHPOB-BBWFWOEESA-N mitiglinide Chemical compound C([C@@H](CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)C(=O)O)C1=CC=CC=C1 WPGGHFDDFPHPOB-BBWFWOEESA-N 0.000 description 17
- 229960003365 mitiglinide Drugs 0.000 description 13
- 230000000291 postprandial effect Effects 0.000 description 10
- 206010003210 Arteriosclerosis Diseases 0.000 description 9
- 208000011775 arteriosclerosis disease Diseases 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 230000003914 insulin secretion Effects 0.000 description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 230000002060 circadian Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- CZMRCDWAGMRECN-UHFFFAOYSA-N 2-{[3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- -1 depots Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 244000060011 Cocos nucifera Species 0.000 description 2
- 235000013162 Cocos nucifera Nutrition 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 229960000698 nateglinide Drugs 0.000 description 2
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 229960001466 acetohexamide Drugs 0.000 description 1
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960004111 buformin Drugs 0.000 description 1
- XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000008529 pathological progression Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 1
- 229960002277 tolazamide Drugs 0.000 description 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 229960001729 voglibose Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- a pharmaceutical composition for improving or treating impaired glucose tolerance, borderline diabetes, insulin resistance and hyperinsulinemia comprising a hypoglycemic agent
- the present invention relates to a therapeutic agent for preventing the onset and progress of borderline diabetes treatment or borderline diabetic power diabetes or macrovascular disorders such as arteriosclerosis and myocardial infarction.
- Non-patent Document 1 Those who cannot rule out the possibility of diabetes are those who have hemoglobin Ale strength of .6% or more and less than 6.1% and who have not been treated for diabetes.
- Diabetes is diagnosed if any one of blood glucose ⁇ 126 mg / dl, occasional blood glucose ⁇ 200 mg / dl, or 2-hour blood glucose ⁇ 200 mg / dl in the 75 g transglucose tolerance test (OGTT) is confirmed (Diabetes Car e 20: 1183 (1997), Diabet Med 15: 539 (1998), diabetes 42: 385 (1999), non-patent literature 2-4).
- Measurements of fasting blood glucose levels such as the fact that blood glucose levels fluctuate significantly at any time while eating, and the effort to carry out the 75-g glucose tolerance test is laborious. Has been prioritized. Under these circumstances, the possibility of diabetes cannot be ruled out!
- Glinide oral hypoglycemic drugs consisting of mitiglinide, nateglinide, and repaglinide are widely used as fast-acting insulin secretagogues, and increase postprandial blood glucose levels by recovering diminished early postprandial insulin secretion in diabetic patients. It is a drug characterized by suppressing However, it has been clinically confirmed whether the administration of these drugs to people in borderline areas is effective for subsequent pathological progression. The possibility of diabetes can not be denied! / Various investigation results show that about 8.8 million people listed as people receive diabetes treatment, but there is an increased risk of arteriosclerosis As a result, early intervention and drug intervention for these people are extremely effective in preventing the development of metabolic syndrome through improvement of hyperinsulinemia and insulin resistance. It is an important point.
- Non-Patent Document 1 Ministry of Health, Labor and Welfare Health Bureau General Affairs Division Lifestyle Disease Control Office Survey, 2003
- Non-Patent Document 2 Diabetes Care 20: 1183 (1997)
- Non-Patent Document 3 Diabet Med 15: 539 (1998)
- Non-Patent Document 4 Diabetes 42: 385 (1999)
- Non-Patent Document 5 Lancet 354: 617 (1999)
- Non-Patent Document 6 Diabetes Care 22: 920 (1999)
- the present invention improves hyperinsulinemia, insulin resistance, and postprandial hyperglycemia by restoring insulin secretion in the early postprandial period for people with impaired glucose tolerance (IGT) and borderline diabetes.
- the objective is to provide drugs to prevent the progression of metabolic syndrome including arteriosclerosis.
- the present inventors focused on the fact that glinide drugs restore early postprandial insulin secretion, and started IGT gradual force administration to improve postprandial delayed insulin secretion and increase high insulin secretion. It was found that blood sugar can be lowered with a small amount of insulin by correcting blood glucose and improving insulin sensitivity throughout the body.
- the present inventors administered mitiglinide as a glinide drug to Zucker Fatty rats, which are IGT model animals, and examined circadian fluctuations in blood glucose and insulin and systemic insulin sensitivity.
- mitiglinide could be administered over 4 weeks, suppressing excessive secretion of insulin after meals, and improving systemic insulin sensitivity.
- the present inventors have completed the present invention related to the prevention or treatment of borderline diabetes based on such findings.
- the present invention provides an impaired glucose tolerance, borderline sugar containing a hypoglycemic agent as an active ingredient.
- a pharmaceutical composition for mania treatment that improves urine disease, insulin resistance and hyperinsulinemia.
- the present invention also includes a hypoglycemic agent as an active ingredient, preventing the development of impaired glucose tolerance, borderline diabetes, insulin resistance and hyperinsulinemia to diabetes mellitus (DM) or metabolic syndrome.
- a delayed pharmaceutical composition is provided.
- the present invention also easily causes macrovascular disorders, cardiovascular events and ischemic heart disease from impaired glucose tolerance, borderline diabetes, insulin resistance and hyperinsulinemia, which contains a hypoglycemic agent as an active ingredient! Providing a pharmaceutical composition for preventing and / or delaying progress to the state.
- the present invention also provides use of a hypoglycemic agent for producing a pharmaceutical composition for improving or treating impaired glucose tolerance, borderline diabetes, insulin resistance and hyperinsulinemia.
- the present invention also provides a blood sugar for producing a pharmaceutical composition for preventing or delaying progression from impaired glucose tolerance, borderline diabetes, insulin resistance and hyperinsulinemia to diabetes mellitus or metabolic syndrome.
- a depressant for preventing or delaying progression from impaired glucose tolerance, borderline diabetes, insulin resistance and hyperinsulinemia to diabetes mellitus or metabolic syndrome.
- the present invention also provides a drug for preventing or delaying the progression from impaired glucose tolerance, borderline diabetes, insulin resistance and hyperinsulinemia to a state prone to macrovascular disorders, cardiovascular events and ischemic heart disease.
- a hypoglycemic agent for the manufacture of a composition is provided.
- the hypoglycemic agent is preferably a hypoglycemic agent that lowers the plasma insulin level after 1 hour of administration by 15 ng / mL or more as compared to the case where the pharmaceutical composition of the present invention is not administered. . It is also preferable to be a hypoglycemic agent that makes the plasma insulin level 1 hour after administration to 45 ng / mL or less.
- a-GI ⁇ -darcosidase inhibitors
- glycinide preparations glycinide preparations
- SU agents sulfourea agents
- BG biguanide
- Examples of a-darcosidase inhibitors include voglibose and carbose.
- (2S) -2-benzyl-4-[(3aR, 7aS) -octahydro-2H-isoindole-2-yl] -4-oxobutanoic acid (generic name: mitiglinide), N- (Trans-4-Isopropylvircyclohexyl) -D-Phelanalanine (generic name: nateglinide),
- S) -2-Ethoxy-4- ⁇ 2-[[3-Methyl-1- [ 2- (1-Pyveridyl) phenol] butyl] amino] -2-oxoethyl ⁇ benzoic acid (generic name: levaglinide) and the like.
- Sulfonylurea agents include tolptamide; chlorpropamide; tolazamide; aceto hexamide; gliclazide; 4-cloguchi-N-[(l-pyrrolidyl-lumino) carbol] -benzenesulfonamide (glyco-pyramide) 1-butyl-3-meta-lylurea; glipizide;
- thiazolidine drugs examples include glitazone drugs such as piodaritazone and oral diglitazone.
- biguanides examples include metformin and buformin.
- Crystal forms, solvates, pharmaceutically acceptable salts and the like of the above hypoglycemic agents can also be used.
- fast-acting insulin secretagogues are preferred, and mitiglinide or a pharmaceutically acceptable salt thereof is particularly preferred.
- the composition of the present invention may be used to improve or treat impaired glucose tolerance (IGT), borderline diabetes, insulin resistance and hyperinsulinemia; from these conditions! Prevention or delay of progress to syndrome; especially in these conditions! / And diseases, especially angina pectoris caused by insulin resistance and hyperinsulinemia, myocardial infarction and arteriosclerosis It is effective in preventing, delaying, and treating the progression of vascular disorders, cardiovascular events, and ischemic heart disease. More particularly, it is effective in improving or treating IGT, insulin resistance and hyperinsulinemia, and preventing or delaying the progression from IGT to diabetes or metabolic syndrome. In particular, it is effective in improving or treating IGT and hyperinsulinemia.
- the term metabolic syndrome has the same meaning as known in the art.
- composition of the present invention preferably contains a glucose-lowering agent in an amount such that a single dose is less than 20 mg, preferably 10 mg or less.
- composition of the present invention is administered by oral administration or parenteral administration (intramuscular, subcutaneous, intravenous, etc.). Oral administration is preferred.
- the dose to be used for the above purpose is determined by the intended therapeutic effect, administration method, treatment period, age, weight, etc., but it is usually given orally as a daily dose for an adult by the oral or parenteral route.
- administration preferably 30 to 60 mg, more preferably 15 to 30 mg, more preferably 7.5 to 15 mg is used, and in the case of parenteral administration, 100 g to 60 mg or less is preferably used. It is preferable to administer immediately before every meal.
- composition of the present invention when the composition of the present invention is prepared as an oral preparation, after adding an excipient, and if necessary, a binder, a disintegrant, a lubricant, a coloring agent, a flavoring agent and the like.
- excipients include lactose, corn starch, saccharose, butu sugar, sorbit, crystalline cellulose, etc. , Tragacanth, gelatin, shellac, hydroxypropyl cellulose, hydroxypropyl starch, polybulurpyrrolidone, etc.
- disintegrants examples include starch, agar, gelatin powder, crystalline cellulose, calcium carbonate, sodium bicarbonate, calcium citrate, dextst Orchids, pectin, etc., lubricants such as magnesium stearate, talc, polyethylene glycol, silica, hydrogenated vegetable oil, etc. are permitted to be added to pharmaceuticals as coloring agents.
- lubricants such as magnesium stearate, talc, polyethylene glycol, silica, hydrogenated vegetable oil, etc. are permitted to be added to pharmaceuticals as coloring agents.
- cocoa powder, coconut powder, coconut brain, aromatic acid, potato oil, coconut oil, dragon brain, cinnamon powder, etc. are used.
- these tablets or granules may be coated with sugar, gelatin or other appropriate coatings.
- pH adjusters, buffers, stabilizers, preservatives, etc. may be added as necessary to make subcutaneous, intramuscular and intravenous injections by conventional methods.
- ZF rats Zucker Fatty rats with the characteristics of obesity and insulin resistance. Although ZF rats show hyperinsulinemia and impaired glucose tolerance, fasting blood glucose is in the normal range and is known to exhibit pathologies similar to human-defined IGT (Br J Pharmacol 125, 1708-14). 1998).
- Rats Six-week-old male Zucker Fatty rats were introduced and acclimated to restricted feeding twice a day for 1 hour each (9:00 am to 10:00 am, 15:00 to 16:00 pm). Rats were randomly divided into two groups after a 1-week acclimation period and administered drugs for 4 weeks. In one group, mitiglinide suspended in 0.5% methylcellulose as a drug was administered at a dose of 3mg / kg, and in the other group, only 0.5% methylcellulose solution as the administration medium was administered twice a day immediately before each meal. Forced oral administration. Circadian fluctuations in blood glucose and insulin were measured at the start of administration and at 4 weeks after the start of administration, under the restricted feeding twice a day.
- ITT insulin tolerance test
- ITT was conducted to more accurately quantify the degree of improvement in insulin sensitivity throughout the body.
- Insulin injection is a characteristic that blood glucose is temporarily reduced. Insulin resistance is strong, and in some cases, insulin injection does not show a significant decrease in blood glucose.
- Fig. 3 in the case of ZF rats, even when insulin was administered, the blood glucose level decreased to about 70% of the pre-dose value 60 minutes after administration, and did not decrease.
- mitiglinide treatment decreased blood glucose to about 50% before administration 60 minutes after insulin administration.
- a comparison of total blood glucose levels after insulin administration clearly showed a low value in the mitiglinide group as shown in Table 2, suggesting an improvement in insulin resistance.
- mitiglinide treatment from the IGT stage can improve insulin resistance or hyperinsulinemia, which is considered to be a factor promoting the progression of arteriosclerosis. It was thought that the progress from IGT to DM or so-called metabolic syndrome could be suppressed.
- FIG. 1 shows the results of investigating the effect of mitiglinide treatment on circadian fluctuations in blood glucose.
- FIG. 2 shows the results of examining the effect of mitiglinide treatment on circadian variation of insulin.
- FIG. 3 shows the results of the insulin tolerance test.
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06712691A EP1891971A4 (en) | 2005-01-31 | 2006-01-31 | MEDICAL COMPOSITION USING HYPERGLY CRAB MEDICAMENT TO TREAT OR TREAT GLUCOSE-INTOLERANCE, BORDERLINE DIABETES, INSULIN RESISTANCE AND HYPERINSULINEMIA |
JP2007500648A JP4974057B2 (ja) | 2005-01-31 | 2006-01-31 | 血糖降下剤を含有する、耐糖能異常、境界型糖尿病、インスリン抵抗性及び高インスリン血症の改善ないし治療用医薬組成物 |
US11/831,211 US20070275999A1 (en) | 2005-01-31 | 2007-07-31 | Pharmaceutical compositions containing a hypoglycemic agent(s) for improving or treating impaired glucose tolerance, borderline diabetes, insulin resistance or hyperinsulinemia |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005023289 | 2005-01-31 | ||
JP2005-023289 | 2005-01-31 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/831,211 Continuation US20070275999A1 (en) | 2005-01-31 | 2007-07-31 | Pharmaceutical compositions containing a hypoglycemic agent(s) for improving or treating impaired glucose tolerance, borderline diabetes, insulin resistance or hyperinsulinemia |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006080524A1 true WO2006080524A1 (ja) | 2006-08-03 |
Family
ID=36740540
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/301548 WO2006080524A1 (ja) | 2005-01-31 | 2006-01-31 | 血糖降下剤を含有する、耐糖能異常、境界型糖尿病、インスリン抵抗性及び高インスリン血症の改善ないし治療用医薬組成物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20070275999A1 (ja) |
EP (1) | EP1891971A4 (ja) |
JP (1) | JP4974057B2 (ja) |
KR (1) | KR20070102694A (ja) |
CN (1) | CN101111266A (ja) |
WO (1) | WO2006080524A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8563730B2 (en) | 2008-05-16 | 2013-10-22 | Takeda San Diego, Inc. | Pyrazole and fused pyrazole glucokinase activators |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20070104953A (ko) * | 2000-03-17 | 2007-10-29 | 아지노모토 가부시키가이샤 | 신경 장애용 약제 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09502727A (ja) * | 1993-09-15 | 1997-03-18 | 三共株式会社 | Niddmの発症を阻止又は遅延するためのチアゾリジンジオン類の用途 |
JPH11236337A (ja) * | 1997-12-10 | 1999-08-31 | Takeda Chem Ind Ltd | 耐糖能異常改善剤 |
JP2003518496A (ja) * | 1999-12-23 | 2003-06-10 | ノバルティス アクチエンゲゼルシャフト | グルコース代謝障害を処置するための血糖降下薬の使用 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6354321A (ja) * | 1985-03-27 | 1988-03-08 | Ajinomoto Co Inc | 血糖降下剤 |
AU654331B2 (en) * | 1991-03-30 | 1994-11-03 | Kissei Pharmaceutical Co. Ltd. | Succinic acid compounds |
NO179246C (no) * | 1991-11-20 | 1996-09-04 | Sankyo Co | Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav |
US5457109A (en) * | 1993-09-15 | 1995-10-10 | Warner-Lambert Company | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus |
NO305987B1 (no) * | 1994-04-11 | 1999-08-30 | Sankyo Co | Heterosykliske forbindelser med antidiabetisk aktivitet, deres anvendelse og farmasoeytisk preparat inneholdende disse |
US6006753A (en) * | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
ES2364145T3 (es) * | 1996-11-15 | 2011-08-25 | Ajinomoto Co., Inc. | Composición de nateglinida en comprimidos. |
ID21411A (id) * | 1997-12-10 | 1999-06-10 | Takeda Chemical Industries Ltd | Agen untuk mengobati daya tahan glukosa yang berisiko tinggi rusak |
US6100300A (en) * | 1998-04-28 | 2000-08-08 | Bristol-Myers Squibb Company | Metformin formulations and method for treating intermittent claudication employing same |
US6559188B1 (en) * | 1999-09-17 | 2003-05-06 | Novartis Ag | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes |
DE60007592T2 (de) * | 1999-09-30 | 2004-09-16 | Pfizer Products Inc., Groton | Bicyclische Pyrrolylamide als Glycogenphosphorylase-Inhibitoren |
US6586438B2 (en) * | 1999-11-03 | 2003-07-01 | Bristol-Myers Squibb Co. | Antidiabetic formulation and method |
JP4822039B2 (ja) * | 1999-12-28 | 2011-11-24 | 味の素株式会社 | 経口投与用糖尿病薬製剤 |
KR20070104953A (ko) * | 2000-03-17 | 2007-10-29 | 아지노모토 가부시키가이샤 | 신경 장애용 약제 |
ATE373635T1 (de) * | 2000-10-18 | 2007-10-15 | Ajinomoto Kk | Verfahren zur herstellung von acylphenylalaninen |
DE60129728T2 (de) * | 2000-10-18 | 2008-04-24 | Ajinomoto Co., Inc. | Verfahren zur herstellung von nateglinid-kristallen |
EP1334964B1 (en) * | 2000-10-24 | 2007-08-15 | Ajinomoto Co., Inc. | Process for producing b-form nateglinide crystal |
CA2426263C (en) * | 2000-10-24 | 2010-05-25 | Ajinomoto Co., Inc. | Nateglinide-containing preparation |
JP2004513935A (ja) * | 2000-11-17 | 2004-05-13 | ノボ ノルディスク アクティーゼルスカブ | グルカゴンアンタゴニスト/逆アゴニスト |
US6652838B2 (en) * | 2001-04-05 | 2003-11-25 | Robert E. Weinstein | Method for treating diabetes mellitus |
FR2834214B1 (fr) * | 2001-12-28 | 2004-09-24 | Lipha | Composition pharmaceutique comprenant un inhibiteur d'alpha-glucosidase et un acide 4-oxo-butanoique et son utilisation pour traiter le diabete |
US6830759B2 (en) * | 2002-06-28 | 2004-12-14 | Ajinomoto Co., Inc. | Antidiabetic preparation for oral administration |
US7071341B2 (en) * | 2003-02-28 | 2006-07-04 | Council Of Scientific And Industrial Research | α-Glucosidase inhibitors and their synthesis from a natural source |
-
2006
- 2006-01-31 EP EP06712691A patent/EP1891971A4/en not_active Withdrawn
- 2006-01-31 JP JP2007500648A patent/JP4974057B2/ja not_active Expired - Fee Related
- 2006-01-31 CN CNA2006800036755A patent/CN101111266A/zh active Pending
- 2006-01-31 KR KR1020077017470A patent/KR20070102694A/ko not_active Application Discontinuation
- 2006-01-31 WO PCT/JP2006/301548 patent/WO2006080524A1/ja active Application Filing
-
2007
- 2007-07-31 US US11/831,211 patent/US20070275999A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09502727A (ja) * | 1993-09-15 | 1997-03-18 | 三共株式会社 | Niddmの発症を阻止又は遅延するためのチアゾリジンジオン類の用途 |
JP2000273043A (ja) * | 1993-09-15 | 2000-10-03 | Sankyo Co Ltd | ピオグリタゾンを含有する耐糖能不全治療剤 |
JPH11236337A (ja) * | 1997-12-10 | 1999-08-31 | Takeda Chem Ind Ltd | 耐糖能異常改善剤 |
JP2003518496A (ja) * | 1999-12-23 | 2003-06-10 | ノバルティス アクチエンゲゼルシャフト | グルコース代謝障害を処置するための血糖降下薬の使用 |
Non-Patent Citations (4)
Title |
---|
HIROSE T. ET AL.: "The effects of nateglinide following oral glucose load in impaired glucose tolerance subjects: Rapid insulin stimulation by nateglinide in IGT subjects", ENDOCRINE JOURNAL, vol. 49, no. 6, 2002, pages 649 - 652, XP003000905 * |
OJIMA K. ET AL.: "Rapid Onset-Insulinotropic Effect of Mitiglinide Calcium Dihydrate (KAD-1229), a Novel Antipostprandial Hyperglycemic Agent: Comparison with Nateglinide", JAPANESE PHARMACOLOGY AND THERAPEUTICS, vol. 32, no. 2, 2004, pages 73 - 80, XP003000908 * |
SALORANTA C. ET AL.: "Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population", DIABETES CARE, vol. 25, no. 12, 2002, pages 2141 - 2146, XP003000904 * |
See also references of EP1891971A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8563730B2 (en) | 2008-05-16 | 2013-10-22 | Takeda San Diego, Inc. | Pyrazole and fused pyrazole glucokinase activators |
US9139598B2 (en) | 2008-05-16 | 2015-09-22 | Takeda California, Inc. | Glucokinase activators |
Also Published As
Publication number | Publication date |
---|---|
JPWO2006080524A1 (ja) | 2008-06-19 |
CN101111266A (zh) | 2008-01-23 |
EP1891971A4 (en) | 2010-02-03 |
EP1891971A1 (en) | 2008-02-27 |
JP4974057B2 (ja) | 2012-07-11 |
US20070275999A1 (en) | 2007-11-29 |
KR20070102694A (ko) | 2007-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1011673B1 (en) | Novel niddm regimen | |
Culy et al. | Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus | |
US20010031790A1 (en) | Treatment for complications of type 2 diabetes | |
WO2005110394A1 (ja) | 糖尿病治療薬 | |
US20220184006A1 (en) | Combination therapy | |
US20190134023A1 (en) | Method of Restoring the Incretin Effect | |
WO2006080524A1 (ja) | 血糖降下剤を含有する、耐糖能異常、境界型糖尿病、インスリン抵抗性及び高インスリン血症の改善ないし治療用医薬組成物 | |
CA2591416A1 (en) | Medicinal composition containing fbpase inhibitor | |
WO2001000196A2 (en) | Mirtazapine for weight gain in wasting diseases | |
WO2017022787A1 (ja) | 収縮力低下随伴性排尿筋過活動改善剤 | |
US20050222262A1 (en) | Novel NIDDM regimen | |
JP2005132799A (ja) | 本態性振戦の予防・治療剤 | |
US20130184350A1 (en) | Novel NIDDM Regimen | |
KR20210089176A (ko) | 통풍 또는 고요산혈증의 치료를 위한 의약품의 제조에서의 화합물 a 및 화합물 b의 공동 용도 | |
Nakanishi et al. | Circadian blood pressure rhythm analysis of the usefulness of combination therapy with a calcium antagonist and an angiotensin converting enzyme inhibitor | |
JP2006193511A (ja) | 糖尿病の治療のための医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007500648 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077017470 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200680003675.5 Country of ref document: CN Ref document number: 11831211 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006712691 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11831211 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2006712691 Country of ref document: EP |